Environment International (Oct 2020)
Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetes
- Aidan McGlinchey,
- Tim Sinioja,
- Santosh Lamichhane,
- Partho Sen,
- Johanna Bodin,
- Heli Siljander,
- Alex M. Dickens,
- Dawei Geng,
- Cecilia Carlsson,
- Daniel Duberg,
- Jorma Ilonen,
- Suvi M. Virtanen,
- Hubert Dirven,
- Hanne Friis Berntsen,
- Karin Zimmer,
- Unni C. Nygaard,
- Matej Orešič,
- Mikael Knip,
- Tuulia Hyötyläinen
Affiliations
- Aidan McGlinchey
- School of Medical Sciences, Örebro University, 702 81 Örebro, Sweden
- Tim Sinioja
- School of Science and Technology, Örebro University, 702 81 Örebro, Sweden
- Santosh Lamichhane
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland
- Partho Sen
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland
- Johanna Bodin
- Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, 0456 Oslo, Norway
- Heli Siljander
- Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland
- Alex M. Dickens
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland
- Dawei Geng
- School of Science and Technology, Örebro University, 702 81 Örebro, Sweden
- Cecilia Carlsson
- School of Science and Technology, Örebro University, 702 81 Örebro, Sweden
- Daniel Duberg
- School of Science and Technology, Örebro University, 702 81 Örebro, Sweden
- Jorma Ilonen
- Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, 20014 Turku, Finland; Department of Clinical Microbiology, Turku University Hospital, 20014 Turku, Finland
- Suvi M. Virtanen
- Public Health Promotion Unit, National Institute for Health and Welfare, 00271 Helsinki, Finland; Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Research, Development and Innovation Center, Tampere, Finland; Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland
- Hubert Dirven
- Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, 0456 Oslo, Norway
- Hanne Friis Berntsen
- Norwegian University of Life Sciences, 0102 Oslo, Norway; National Institute of Occupational Health, 0363 Oslo, Norway
- Karin Zimmer
- Tampere University Hospital, Research, Development and Innovation Center, Tampere, Finland
- Unni C. Nygaard
- Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, 0456 Oslo, Norway
- Matej Orešič
- School of Medical Sciences, Örebro University, 702 81 Örebro, Sweden; Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland; Corresponding authors at: School of Science and Technology, Örebro University, 702 81 Örebro, Sweden (M. Orešič). Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland (M. Knip). MTM Research Centre, School of Science and Technology, Örebro University, 702 81 Örebro, Sweden (T. Hyötyläinen).
- Mikael Knip
- Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland; Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Research, Development and Innovation Center, Tampere, Finland; Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland; Corresponding authors at: School of Science and Technology, Örebro University, 702 81 Örebro, Sweden (M. Orešič). Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland (M. Knip). MTM Research Centre, School of Science and Technology, Örebro University, 702 81 Örebro, Sweden (T. Hyötyläinen).
- Tuulia Hyötyläinen
- School of Science and Technology, Örebro University, 702 81 Örebro, Sweden; Corresponding authors at: School of Science and Technology, Örebro University, 702 81 Örebro, Sweden (M. Orešič). Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland (M. Knip). MTM Research Centre, School of Science and Technology, Örebro University, 702 81 Örebro, Sweden (T. Hyötyläinen).
- Journal volume & issue
-
Vol. 143
p. 105935
Abstract
In the last decade, increasing incidence of type 1 diabetes (T1D) stabilized in Finland, a phenomenon that coincides with tighter regulation of perfluoroalkyl substances (PFAS). Here, we quantified PFAS to examine their effects, during pregnancy, on lipid and immune-related markers of T1D risk in children. In a mother-infant cohort (264 dyads), high PFAS exposure during pregnancy associated with decreased cord serum phospholipids and progression to T1D-associated islet autoantibodies in the offspring. This PFAS-lipid association appears exacerbated by increased human leukocyte antigen-conferred risk of T1D in infants. Exposure to a single PFAS compound or a mixture of organic pollutants in non-obese diabetic mice resulted in a lipid profile characterized by a similar decrease in phospholipids, a marked increase of lithocholic acid, and accelerated insulitis. Our findings suggest that PFAS exposure during pregnancy contributes to risk and pathogenesis of T1D in offspring.
